



PRESS RELEASE

AB Science's Board of Directors is restructuring its governance to usher in a new phase in the company's development

Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer

Paris, July 7, 2026

The Board of Directors of AB Science S.A. (the "Company" or "AB Science," Euronext – FR0010557264 – AB), meeting today, decided to evolve the company's governance structure to support a new phase of its development.

In this context, the Board of Directors co-opted Mr. Stéphane LEDERMANN as a director to replace Mr. Renaud SASSI, who wished to step down from his position as director. The Board of Directors would like to warmly thank Mr. Renaud SASSI for his commitment, professionalism, and the quality of his contributions to the Board's work throughout his tenure.

During this meeting, following a lively and constructive discussion, the Board of Directors also appointed Mr. Stéphane LEDERMANN as Chairman and Chief Executive Officer.

A shareholder of the company for more than fourteen years, Mr. Stéphane LEDERMANN has actively contributed, both directly and indirectly by bringing together other investors, to the company's financing. His dedication to the company, his understanding of its challenges, and his proven ability to lead and finance innovative companies are major assets for steering this new phase.

The Board of Directors has decided to entrust its new Chairman and Chief Executive Officer with conducting a strategic review of the company's operations, assets, and prospects.

The conclusions of this review will be presented to the Board of Directors and will lead to the presentation of a strategic roadmap to the market next fall.

On this occasion, Mr. Alain MOUSSY, co-founder of AB Science, is stepping down from his role as Chairman and Chief Executive Officer but will remain a director. The Board of Directors wishes to acknowledge his entrepreneurial vision, his unwavering commitment, and his pivotal role in building and developing the company over the years.

The Board of Directors reaffirms its confidence in the quality of AB Science's teams, their ability to maximize the value of assets already in development, and to continue seeking strategic partnerships.

Mr. Stéphane LEDERMANN stated: *"I thank the Board of Directors for the trust it has placed in me. I approach this role with deep respect for the company's track record and the work accomplished over the past 25 years. Drawing on the trust I have earned over the past few years as an investor in the company and my experience in multidisciplinary management and innovation financing, I will lead—together with the Board and the management team—an in-depth strategic review aimed at identifying the best opportunities to maximize the value of our assets. Our goal is to present, this fall, a clear and realistic roadmap accompanied by a rigorous implementation schedule."*

Biography of Stéphane LEDERMANN

Stéphane LEDERMANN is an executive specializing in the development and financing of innovative companies. With more than thirty years of experience, he has held executive and financial leadership positions at industrial groups, technology startups, business aviation companies, and real estate development firms. Throughout his career, he has led numerous corporate audit, valuation, and financing initiatives, supporting investors, *private equity* funds, and innovative companies in their growth projects.

Appointed CEO of Boostheat in January 2025, he led a major turnaround plan aimed at stabilizing the company's financial structure and sustainably reducing its recurring expenses. He is stepping down from all his other operational roles to devote himself fully to his new responsibilities.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

For more information about the Company, visit the website: www.ab-science.com.

For further information, please contact:

ACTUS Finance & Communication

Emmanuel DOVERGNE

Investor Relations

Phone: +33 (0)7 88 09 17 29

Email: edovergne@actus.fr

Anne-Charlotte DUDICOURT

Media Relations

Phone: +33 (0)6 24 03 26 52

Email: acdudicourt@actus.fr